The 36-month beta value for ALIM is also noteworthy at 1.24. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALIM is 50.86M, and at present, short sellers hold a 1.32% of that float. The average trading volume of ALIM on September 04, 2024 was 494.47K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ALIM) stock’s latest price update
Alimera Sciences Inc. (NASDAQ: ALIM)’s stock price has plunge by 0.00relation to previous closing price of 5.52. Nevertheless, the company has seen a -1.25% plunge in its stock price over the last five trading sessions. zacks.com reported 2024-08-06 that Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.44 per share a year ago.
ALIM’s Market Performance
ALIM’s stock has fallen by -1.25% in the past week, with a monthly drop of -0.54% and a quarterly rise of 77.49%. The volatility ratio for the week is 0.76% while the volatility levels for the last 30 days are 0.53% for Alimera Sciences Inc. The simple moving average for the last 20 days is -0.96% for ALIM stock, with a simple moving average of 34.96% for the last 200 days.
Analysts’ Opinion of ALIM
Maxim Group, on the other hand, stated in their research note that they expect to see ALIM reach a price target of $10. The rating they have provided for ALIM stocks is “Buy” according to the report published on March 25th, 2024.
Alliance Global Partners gave a rating of “Buy” to ALIM, setting the target price at $8 in the report published on October 30th of the previous year.
ALIM Trading at -0.78% from the 50-Day Moving Average
After a stumble in the market that brought ALIM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.30% of loss for the given period.
Volatility was left at 0.53%, however, over the last 30 days, the volatility rate increased by 0.76%, as shares sank -0.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.18% lower at present.
During the last 5 trading sessions, ALIM fell by -1.07%, which changed the moving average for the period of 200-days by +68.09% in comparison to the 20-day moving average, which settled at $5.57. In addition, Alimera Sciences Inc. saw 27.78% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALIM starting from Caligan Partners LP, who purchase 579,000 shares at the price of $3.39 back on Sep 14 ’23. After this action, Caligan Partners LP now owns 16,835,154 shares of Alimera Sciences Inc., valued at $1,962,810 using the latest closing price.
Caligan Partners LP, the 10% Owner of Alimera Sciences Inc., sale 579,000 shares at $3.39 during a trade that took place back on Sep 14 ’23, which means that Caligan Partners LP is holding 16,256,154 shares at $1,962,810 based on the most recent closing price.
Stock Fundamentals for ALIM
Current profitability levels for the company are sitting at:
- 0.01 for the present operating margin
- 0.77 for the gross margin
The net margin for Alimera Sciences Inc. stands at -0.15. The total capital return value is set at 0.01. Equity return is now at value -34.57, with -9.63 for asset returns.
Based on Alimera Sciences Inc. (ALIM), the company’s capital structure generated 0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.08. The debt to equity ratio resting at 1.81. The interest coverage ratio of the stock is 0.09.
Currently, EBITDA for the company is 7.28 million with net debt to EBITDA at 30.96. When we switch over and look at the enterprise to sales, we see a ratio of 3.63. The receivables turnover for the company is 2.69for trailing twelve months and the total asset turnover is 0.66. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.79.
Conclusion
In summary, Alimera Sciences Inc. (ALIM) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
